Medical science has traveled a long distance in technological advancement. Particularly, last three decades have witnessed great changes in the technology related with diagnosis and treatment of diseases. No branch of medical science whether neurology or gastroenterology is left untouched of this technological revolution. Neurology is the system of coordination and control of body. Many efforts have been made to find out the relationship between ailments of body with neurological imbalance of the body. The results are wonderful; now many incurable diseases can be cured by proper stimulation of neurological system of the body. Obesity is one among such major diseases.

Obesity is the result of excessive intake of food which later is accumulated in the body beneath the skin in the form of fat, giving the body a bulky look. Our neurological system has a control over our dietary habits. Before eating anything we get permission from our brain. The brain permits us only when it will have the signal of hunger sent to it by the cells of the body. A neuro-receptor named as endo-cannabinoid-1 (CB-1) sends the signals of hunger to the brain. This receptor is a part of our neurological system. This way a smooth coordination is established between our brain and digestive system. Whenever, there is some unbalancing in the functioning of the CB-1 receptor, a person can start eating excessive food.

Acomplia, the oral prescription diet pill can help in such a situation by inhibiting the functioning of CB-1 receptor. The active constituent of Acomplia is Rimonabant which have the tendency of blocking CB-1 receptor. Initially Rimonabant was clinically tested by Sanofi-Aventis as an anti-smoking drug because the same CB-1 receptor is also responsible for carrying the signal of urge for smoking to the brain. During this testing Acomplia (Rimonabant) is found very effective in curbing enormous urge for food. After rigorous clinical tests the drug manufacturer Sanofi-Aventis launched Acomplia in the UK anti-obesity drug market in the month of June. The popularity of drug among the people of the UK is a proof of its efficacy.

The launch of this drug is anticipated in many other countries; Germany, Denmark, Norway, Ireland and Finland are the prominent among those countries. FDA approval for Acomplia is in the line only after that the drug will be launched in the US anti-obesity drug market most probably by the name of Zimulti. Sanofi-Aventis is highly anticipative to get approval soon.

Acomplia may have some initial mild side-effects in some people like constipation, stomach disorder, nausea, dizziness, anxiety and headache. However these side effects are mild generally disappear with continuous use of the drug for few days. Pregnant ladies and breast feeding mothers must avoid using Acomplia.

Doctor's prescription and advice for starting the use of Acomplia is essential. Both prescription and advice for Acomplia are available through online pharmacies. They may or may not charge for their service; confirm this thing beforehand.